TB-500: Benefits, Mechanism, the “Wolverine” Stack & Dosing — What the Research Actually Shows

TB-500 is the synthetic 7-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4. It drives cell migration, wound contraction, angiogenesis, and reduced inflammation — and it’s the peptide most often stacked with BPC-157 in the “Wolverine” recovery protocol.

What is TB-500?

TB-500 is the common research name for the synthetic acetylated heptapeptide Ac-LKKTETQ — the bioactive fragment corresponding to amino acids 17–23 of the full 43-amino-acid thymosin beta-4 (Tβ4) protein. While some vendors and older literature use “TB-500” interchangeably with full Tβ4, they are distinct. Full Tβ4 has been studied in clinical trials (notably RegeneRx’s RGN-259 ophthalmic formulation), whereas the fragment is the version most commonly used in systemic research-peptide contexts for its actin-regulating core activity.

How does TB-500 work? (Mechanism of action)

The primary and best-characterized mechanism is G-actin sequestration — TB-500 manages the cell’s pool of actin monomers so they’re ready to assemble exactly where repair is needed:

• G-actin binding — binds monomeric G-actin in a 1:1 complex via the LKKTETQ motif.
• Monomer pool maintenance — prevents spontaneous polymerization while keeping a large soluble pool of actin monomers on standby.
• Directional assembly — at injury sites, local signals release the pool, enabling rapid directional F-actin filament assembly.
• Downstream repair — enhanced cell migration, wound contraction, angiogenesis, reduced pro-inflammatory signaling, and support for tissue remodeling.
• Additional effects — anti-apoptotic activity, stem-cell recruitment signals, and extracellular-matrix modulation observed across models.

The science: key studies & findings

Preclinical research on thymosin beta-4 and its active fragments is broad and consistent. Notable threads include:

• Soft-tissue & wound repair — accelerated wound healing, improved tendon repair in canine models, cardiac protection post-infarct, reduced inflammation, and enhanced angiogenesis across multiple tissue types. Explore the literature →
• Clinical development (full Tβ4) — focused on the full 43-amino-acid molecule via RegeneRx’s RGN-259 (0.1% ophthalmic solution) for dry eye disease and neurotrophic keratitis, with Phase 2/3 data supporting safety and efficacy in ocular surface healing. Read more about RGN-259 →
• The fragment (TB-500) — robust supporting preclinical literature on soft-tissue repair, but lacking dedicated large-scale human pharmacokinetic or efficacy trials for systemic musculoskeletal use.

Claimed benefits & research-backed effects

Researchers and experienced users most frequently associate TB-500 with:

• Faster recovery from muscle strains, tendon/ligament injuries, and soft-tissue trauma.
• Reduced swelling and inflammation at injury sites.
• Improved flexibility and reduced “tightness” during healing.
• Support for chronic or stubborn connective-tissue issues, especially when stacked with BPC-157.
• Potential systemic benefits for wound healing and tissue remodeling.

Improvements in mobility and reduced downtime are commonly reported within the first 2–4 weeks of consistent use, particularly when combined with localized BPC-157 — though this is anecdotal.

Typical research protocols & dosing

Educational reference only. The figures below summarize protocols reported in the literature and research community — they are not dosing guidance for any human use.

Goal	Common dose	Frequency	Route	Typical cycle	Notes
Loading / acute injury	2.0–2.5 mg	2× per week	SubQ or IM	4–6 weeks	Most common starting protocol
Maintenance / ongoing	2.0–5.0 mg weekly	1–2× per week	SubQ	After loading phase	Lower frequency as healing progresses
Stubborn tendinopathy	2.0–2.5 mg	2× per week	SubQ near site	6–8 weeks	Often stacked with BPC-157
General recovery / wellness	2.0 mg	Once weekly	SubQ	4 wks on / 4 off	Periodic use

Cost per typical 4–6 week loading cycle: quality material with a verifiable COA generally ranges $150–350+ depending on vial size and vendor. Prioritize recent, batch-matched third-party testing (e.g., Janoshik HPLC + mass spec).

Stacking note: the classic synergistic protocol is BPC-157 + TB-500 (the “Wolverine Stack”). BPC-157 excels at localized cytoprotection and collagen organization; TB-500 excels at systemic cell migration and actin dynamics. Many researchers run them together for comprehensive soft-tissue recovery — see the BPC-157 Research Profile.

Critical disclaimer & safety notes

Full Tβ4 has been investigated in clinical trials for specific ophthalmic indications, but long-term human safety data for the fragment at research doses is limited. It is banned by WADA for athletes. Always verify purity with an independent, batch-matched COA from a named lab — see our guide, How to Read a Janoshik COA — before any research use.

Bottom line

TB-500 represents one of the most elegant mechanisms in the research-peptide space: a short, targeted fragment that unlocks the body’s own actin machinery for repair. Paired with BPC-157’s complementary cytoprotective effects, it forms one of the most researched and discussed recovery stacks in the field. Treat it with the same rigor you apply to any research material — verify your COA, understand the distinction between fragment and full molecule, and keep expectations grounded in the available evidence.